Kuznetsov AN
Serbia
Research Article
Non-myeloablative Autologous Haematopoietic Stem Cell Transplantation with Consolidation Therapy using Mitoxantrone as a Treatment Option in Multiple Sclerosis Patients
Author(s): Novik AA, Kuznetsov AN, Melnichenko VY, Fedorenko DA, Ionova TI and Gorodokin GV
Novik AA, Kuznetsov AN, Melnichenko VY, Fedorenko DA, Ionova TI and Gorodokin GV
High-dose immunosuppressive therapy with autologous haematopoietic stem cell transplantation (AHSCT) is a new and promising approach to multiple sclerosis (MS) treatment. Recently, the rationale of evolution from myeloablative to non-myeloablative (NM) transplant regimens has been discussed. We aimed to study clinical outcomes in MS patients after NM -AHSCT with consolidation therapy using Mitoxantrone. 55 MS patients were included in this study (mean age - 29.1; male/female - 23/32). Median EDSS at base-line - 4.0 (1.5-8.0), the mean follow-up duration - 26 months (range 9.0 - 50). No transplant related deaths were reported. There were no deaths in the study throughout the follow-up period. The mobilization and transplantation procedures were well tolerated. All the patients responded to the treatment. At long-term follow-up in the group with relapsingremitting MS improvement was dem.. View More»
DOI:
10.4172/2157-7633.1000102